Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Novartis to Conduct Clinical Trial for Flu Vaccine in Japan
September 21, 2009
- Eli Lilly Japan to Achieve Sales of US$1 Bil. This Year
September 21, 2009
- NEW PRODUCTS
September 21, 2009
- ESC Congress in Barcelona
September 21, 2009
- R&D NEWS IN BRIEF
September 21, 2009
- NDA Review Time Shortened in 2008 but Still Far from Target
September 21, 2009
- Korosho Eliminates Redundancies from All-Patient Surveys and EPPV
September 21, 2009
- REGULATORY NEWS IN BRIEF
September 21, 2009
- Bristol-Myers Renews Website
September 21, 2009
- da Vinci Surgical System, V.A.C. ATS Treatment System Recommended for Approval
September 21, 2009
- FDG-PET Test for Pediatric Tumors Recommended for Approval as Advanced Healthcare Service
September 21, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 21, 2009
- Korosho's Proposal Regarding Vaccination against New-Type Flu Acceptable
September 21, 2009
- GSK Enters Urology Market with Avolve
September 21, 2009
- Healthcare Providers to Be Preferentially Vaccinated against New-Type Flu
September 21, 2009
- Novartis Prepares Trial for New-Type Flu Vaccine with Adjuvant
September 14, 2009
- Ono Licenses Asimadoline from Tioga
September 14, 2009
- R&D NEWS IN BRIEF
September 14, 2009
- MEDICAL DEVICE NEWS IN BRIEF
September 14, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 14, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…